Document Detail


Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes.
MedLine Citation:
PMID:  23289965     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Type 2 diabetes mellitus (T2DM) represents a rapidly expanding healthcare challenge. There is a significant need for novel therapies to help patients achieve and maintain glycemic control in order to avoid the long-term microvascular and macrovascular complications associated with the disease. Small molecule allosteric activators of the glucokinase enzyme, an important regulator of glucose homeostasis, have emerged as a potential new class of therapeutics. Glucokinase activators have been shown to effectively lower fasting and postprandial glucose in T2DM patients; however, hypoglycemia emerged as a potential risk limiting their therapeutic potential. To mitigate this risk, recent efforts have focused on the design of liver-specific activators that seek to normalize hepatic glucose uptake and production without potentiating glucose-stimulated insulin secretion.
AREAS COVERED: The article reviews the various drug discovery strategies that have emerged for the development of candidates that selectively activate glucokinase in the liver. Literature from 2000 to 2012 is surveyed including scientific publications, patent applications, conferences and clinical trials.
EXPERT OPINION: Liver selective agents have proven to be an effective strategy for mitigating the hypoglycemia risk that has been historically associated with this mechanism. The ultimate therapeutic potential of this approach will depend on the results of longer patient studies which are currently being conducted with several clinical candidates. The discovery of these liver-specific activators has highlighted several challenges in the design of tissue-selective therapeutics, which will need to be overcome in the future.
Authors:
Jeffrey A Pfefferkorn
Related Documents :
22999165 - Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes an...
23128645 - Neonatal hyperglycaemia increases mortality and morbidity in preterm lambs.
8443485 - Use of mobile screening unit for diabetic retinopathy in rural and urban areas.
16620195 - Influences on screening for chronic diabetes complications in type 1 diabetes.
16050945 - Subcutaneous microdialysis before and after an oral glucose tolerance test: a method to...
6220915 - Streptozotocin-induced elevation of pancreatic taurine content and suppressive effect o...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-06
Journal Detail:
Title:  Expert opinion on drug discovery     Volume:  8     ISSN:  1746-045X     ISO Abbreviation:  Expert Opin Drug Discov     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-22     Completed Date:  2013-08-06     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101295755     Medline TA:  Expert Opin Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  319-30     Citation Subset:  IM    
Affiliation:
Cardiovascular, Metabolic & Endocrine Disease Research Unit, Pfizer Worldwide Research & Development, 620 Memorial Drive, Cambridge, MA 02139, USA. jeffrey.a.pfefferkorn@pfizer.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Diabetes Mellitus, Type 2 / drug therapy
Drug Design
Enzyme Activators / pharmacology*
Glucokinase / metabolism*
Humans
Hypoglycemic Agents / pharmacology*
Liver / enzymology
Chemical
Reg. No./Substance:
0/Enzyme Activators; 0/Hypoglycemic Agents; EC 2.7.1.2/Glucokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ex vivo killing of Enterococcus faecalis and mixed plaque bacteria in planktonic and biofilm culture...
Next Document:  Diffusion of a collaborative care model in primary care: a longitudinal qualitative study.